發(fā)布時(shí)間：2018-03-20 02:31

  本文選題：肝細(xì)胞癌　切入點(diǎn)：亮氨酸拉鏈蛋白　出處：《山東大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:目的探討亮氨酸拉鏈蛋白(LUZP)表達(dá)與肝癌患者臨床病理特征的關(guān)系。方法:選擇接受手術(shù)治療的77例肝癌患者的肝癌及癌旁肝組織,采用實(shí)時(shí)定量PCR法檢測(cè)癌及癌旁肝組織中LUZP mRNA的表達(dá),采用免疫組化法檢測(cè)癌及癌旁肝組織中LUZP蛋白的表達(dá),半定量計(jì)分法對(duì)免疫組化結(jié)果進(jìn)行統(tǒng)計(jì)分析。以癌旁肝組織LUZP mRNA均值為標(biāo)準(zhǔn),將肝癌患者分為L(zhǎng)UZP高表達(dá)、低表達(dá)兩個(gè)水平,比較不同LUZP表達(dá)水平患者的臨床病理特征。結(jié)果:肝癌與癌旁肝組織LUZP mRNA表達(dá)分別為1.87±0.11、0.58±0.05,肝癌組織中LUZP mRNA表達(dá)高于癌旁肝組織(P0.05)。肝癌與癌旁肝組織LUZP蛋白表達(dá)分別為(10.0±1.5)、(4.0士0.5)分,肝癌組織中LUZP蛋白表達(dá)高于癌旁肝組織(P0.05)。以癌旁肝組織LUZP mRNA均值為標(biāo)準(zhǔn),將肝癌患者分為L(zhǎng)UZP高表達(dá)49例、低表達(dá)28例。LUZP高表達(dá)患者侵犯門(mén)靜脈、TNM 1+2期、復(fù)發(fā)的發(fā)生率均高于低表達(dá)患者(P均0.05)。低表達(dá)患者的總生存時(shí)間是36個(gè)月,高表達(dá)患者的總生存時(shí)間是12個(gè)月,LUZP高表達(dá)患者的生存時(shí)間低于低表達(dá)患者(P0.05,OR=1.88,95%CI為1.08～3.30)。結(jié)論:LUZP是肝癌患者預(yù)后的生物學(xué)指標(biāo),其高表達(dá)提示肝癌患者預(yù)后差。
[Abstract]:Objective: to investigate the relationship between the expression of leucine zipper protein (LUZP) and the clinicopathological features of hepatocellular carcinoma (HCC). The expression of LUZP mRNA in cancer and adjacent liver tissues was detected by real-time quantitative PCR, and the expression of LUZP protein was detected by immunohistochemistry. The results of immunohistochemistry were statistically analyzed by semi-quantitative scoring method. According to the mean value of LUZP mRNA in adjacent liver tissues, the patients with liver cancer were divided into two levels: high expression of LUZP and low expression of LUZP. Results: the expression of LUZP mRNA was 1.87 鹵0.110.58 鹵0.05 in hepatocellular carcinoma and paracancerous liver tissues, respectively. The expression of LUZP mRNA in HCC was higher than that in paracancerous liver tissue (P0.05A). The expression of LUZP protein in HCC and paracancerous liver tissues was 10.0 鹵1.5 + 4.0 鹵0.5, respectively. The expression of LUZP protein in HCC tissue was higher than that in paracancerous liver tissue (P0.05). According to the mean value of LUZP mRNA in paracancerous liver tissue, 49 cases of HCC were classified as high expression of LUZP and 28 cases of low expression of LUZP were involved in portal vein TNM12 stage. The incidence of recurrence was higher in patients with low expression than that in patients with low expression (P < 0.05). The total survival time of patients with low expression was 36 months. The total survival time of patients with high expression was 12 months. The survival time of patients with high expression of LUZP was lower than that of patients with low expression of LUZP. Conclusion the survival time of patients with high expression of LUZP is lower than that of patients with low expression of LUZP. Conclusion the survival time of patients with high expression of LUZP is lower than that of patients with low expression of LUZP.
【學(xué)位授予單位】：山東大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.7

【相似文獻(xiàn)】

相關(guān)碩士學(xué)位論文 前1條

1 Ali Faheem;肝癌組織中LUZP表達(dá)變化及其與患者臨床病理特征的關(guān)系[D];山東大學(xué);2017年

，

本文編號(hào)：1637131